PMID: 6985835Jan 15, 1980Paper

Chemoimmunotherapy with Corynebacterium parvum in acute myelocytic leukemia

Cancer
M Eppinger-HelftJ Lein

Abstract

The purpose of this study is to see if immunotherapy with C. parvum and prevention of central nervous system relapse with intrathecal methotrexate can prolong duration of complete remission and survival as well as avoid central nervous system relapse. For induction, three weekly I.V. injections of vincristine and Daunorubicin were given with daily prednisone orally, followed by 5-day courses of Cytosine Arabinoside and 6-mercaptopurine. The patients were randomized to chemotherapy or chemoimmunotherapy. Maintenance consisted of vincristine, Daunorubicin, and prednisone one week every odd month, and a 5-day course of Cytosine Arabinoside and 6-mercaptopurine every even month. Every week, the chemoimmunotherapy group also received, without chemotherapy, one injection of C. parvum 4 mg, subcutaneously. All patients received five weekly injections of intrathecal methotrexate 13 mg/m2 right after complete remission was achieved. Out of 181 evaluable cases, 80 (44%) achieved complete remission, 45 were randomized to chemotherapy, and 35 to chemoimmunotherapy. In the chemoimmunotherapy group 32/35 relapsed, and in the chemotherapy group 36/45. Median duration of complete remission and survival were: for group chemotherapy, 8 and 15 mo...Continue Reading

References

Dec 1, 1977·British Journal of Cancer·J K ReesF G Hayhoe
Dec 1, 1976·Archives of Internal Medicine·E J FreireichJ P Hester
Dec 1, 1976·Archives of Internal Medicine·P H Wiernik
Apr 1, 1976·The British Journal of Surgery·T E Sadler, J E Castro
Nov 1, 1973·British Journal of Cancer·R L PowlesG H Fairley
Dec 1, 1958·Journal of Chronic Diseases·S J CUTLER, F EDERER

❮ Previous
Next ❯

Citations

Dec 1, 1982·Australian and New Zealand Journal of Medicine·C M PatonM G Whiteside
Jun 1, 1982·The American Journal of Medicine·K A Foon, R P Gale

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.